Figure 1From: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer DNA concentration in blood plasma of healthy volunteers not receiving Panagen (control, n = 15) and following daily oral administration of 30 mg Panagen for 1 and 3 months (n = 9). Back to article page